Grail reports Q1 EPS ($3.10), consensus ($3.80)

Reports Q1 revenue $31.8M, consensus $35.2M. Cash, cash equivalents, restricted cash and short-term marketable securities totaled $677.9M as of March 31. “We are pleased with the continued U.S. commercial growth of Galleri, with more than 37,000 Galleri tests completed in the Q1, as well as recent steps to streamline the test ordering process and increase test access,” said Bob Ragusa, CEO at GRAIL (GRAL). “We remain focused on developing the market for population scale multi-cancer early detection, advancing Galleri to unlock broad access, and cost efficiency.”